A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of
FT-4202 and test how well FT-4202 works compared to placebo to improve the amount of
hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the
blood vessels become blocked and cause pain).